SRZN - NASDAQ
Surrozen, Inc.
$24.38
+0.31%Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshotsrzn
Cash at Beginning of Period
Last Annual Value
35.25M
3-Year CAGR
2%
5-Year CAGR
4%
10-Year CAGR
%
Surrozen, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Surrozen, Inc. NASDAQ:SRZN | 35.25M | 12.0% | -0.1% | N/A | |
 Opus Genetics, Inc. NASDAQ:IRD | 30.32M | -10.7% | 13.1% | N/A | |
 Seer, Inc. NASDAQ:SEER | 41.28M | -8.4% | -34.2% | N/A | |
 Tevogen Bio Holdings Inc. NASDAQ:TVGN | 1.05M | -42.3% | 207.3% | N/A | |
 Insight Molecular Diagnostics Inc. NASDAQ:IMDX | 8.64M | -28.1% | -0.5% | 0.8% | |
 Nautilus Biotechnology, Inc. NASDAQ:NAUT | 28.65M | -37.2% | -5.1% | N/A | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | 32.63M | -44.5% | -9.4% | N/A | |
 Quince Therapeutics, Inc. NASDAQ:QNCX | 20.75M | -22.5% | -20.9% | N/A | |
 TScan Therapeutics, Inc. NASDAQ:TCRX | 183.72M | 13.7% | 39.0% | N/A | |
 Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | 36.53M | -7.2% | -8.3% | N/A | |
 Armata Pharmaceuticals, Inc. AMEX:ARMP | 14.77M | -10.8% | 6.4% | 4.7% |
Surrozen, Inc. Fair Value Envelope
Related Guides
Continue your SRZN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.